by Marco Torres

December 14, 2017

from PreventDisease Website






Today, it is estimated that 50 percent of the American population have cholesterol levels that fall outside the accepted healthy range, but,

who defines this range and under what testing protocols?

Many medical professionals are starting to question the current standard of care when it comes to statin therapy, as these cholesterol-lowering medications may not benefit patient populations at all, and in fact may be harming them.


Mainstream medicine has long supported the message that "HDL cholesterol is good and LDL is bad," however it remains at the very least an oversimplification.


LDL is needed by the body to build new muscle, which is important as we age. LDL can protect the brain as we age, and low levels of it can escalate problems such as dementia and memory loss.


Cholesterol is neither "good" nor "bad," and attempts to artificially lower your cholesterol can be quite dangerous, in part because of serious side effects such as muscle damage.

Consider the finding (Lack of Association Between Cholesterol and Coronary Heart Disease Mortality and Morbidity and All-Cause Mortality in Persons Older Than 70 Years) of Dr. Harlan Krumholz of the Department of Cardiovascular Medicine at Yale University, who reported in 1994 in the Journal of the American Medical Association that old people with low cholesterol died twice as often from a heart attack as did old people with a high cholesterol.


Supporters of cholesterol campaigns who routinely provide disinformation about LDL cholesterol consistently ignore this observation, or consider it as a rare exception, produced by chance among a number of studies sponsored by the pharmaceutical industry which have found the opposite.

But it is not an exception; there are now a large number of findings that contradict the lipid hypothesis.


To be more specific, most studies on the elderly have shown that high cholesterol is not a risk factor for coronary heart disease at all. On the Medline database many studies address that question.


Specifically how high cholesterol may protect against infections and atherosclerosis. Dozens of studies have found that high cholesterol does not predict or cause mortality.

Now consider that more than 90% of all cardiovascular disease is seen in people above age 60 also and that almost all studies have found that high cholesterol is not a risk factor for women.


This means that high cholesterol is only a risk factor for less than 5% of those who die from a heart attack.



Ditch LDL Testing

The next time you go in for a medical checkup, your doctor will probably make a mistake that could endanger your life, contends cardiologist Allan Sniderman of McGill University in Montreal, Canada.


Most physicians order what he considers the wrong test to gauge heart disease risk: a standard cholesterol readout, which may indicate levels of low-density lipoprotein (LDL) or non-high density lipoprotein (non-HDL) cholesterol.


What they should request instead, Sniderman argues, is an inexpensive assay for a blood protein known as apolipoprotein B (apoB).


ApoB indicates the number of cholesterol-laden particles circulating in the blood - a better indicator of imbalances within proteins of the body than absolute cholesterol levels.


Sniderman asserts that routine apoB tests, which he says cost as little as $20, would spare millions from unnecessary treatment.


Sniderman and a cadre of other scientists have been stumping for apoB for years, but recent re-analyses of clinical data, together with genetic studies, have boosted their confidence.


At last month's American Heart Association (AHA) meeting in Anaheim, California, for example, Sniderman presented a new take on the National Health and Nutrition Examination Survey (NHANES), a famous census of the U.S. population's health.


The reexamination, which compared people with different apoB levels but the same non-HDL cholesterol readings, crystallizes the importance of measuring the protein, he says.


Across the United States, patients who have the highest apoB readings will suffer nearly 3 million more heart attacks, strokes, and other cardiovascular events in the next 15 years than will people with the lowest levels, Sniderman reported.


As lipidologist Daniel Rader of the University of Pennsylvania Perelman School of Medicine puts it, the question of whether LDL cholesterol is the best measure of cardiovascular risk now has a clear answer:


If future guidelines start to emphasize apoB's diagnostic value and drug companies begin to target it, Ference thinks physicians will eventually pay heed to the protein.

"The argument is that LDL cholesterol is good enough," he says. "But as we move toward more personalized medicine, it's not."




Cholesterol and Chronic Heart Failure


Dr. Donna Vredevoe and her group from the School of Nursery and the School of Medicine, University of California at Los Angeles tested more than 200 patients with severe heart failure with five different antigens and followed them for twelve months.


The cause of heart failure was coronary heart disease in half of them and other types of heart disease (such as congenital or infectious valvular heart disease, various cardiomyopathies and endocarditis) in the rest.


Almost half of all the patients were anergic, and those who were anergic and had coronary heart disease had a much higher mortality than the rest.

Now to the salient point:

to their surprise the researchers found that mortality was higher, not only in the patients with anergy, but also in the patients with the lowest lipid values, including total cholesterol, LDL-cholesterol and HDL-cholesterol as well as triglycerides.

The latter finding was confirmed by Dr. Rauchhaus, this time in co-operation with researchers at several German and British university hospitals.


They found that the risk of dying for patients with chronic heart failure was strongly and inversely associated with total cholesterol, LDL-cholesterol and also triglycerides; those with high lipid values lived much longer than those with low values.


Other researchers have made similar observations.


The largest study (Low Serum Total Cholesterol is Associated with Marked Increase in Mortality in Advanced Heart Failure) has been performed by Professor Gregg C. Fonorow and his team at the UCLA Department of Medicine and Cardiomyopathy Center in Los Angeles.


The study, led by Dr. Tamara Horwich, included more than a thousand patients with severe heart failure.


After five years 62 percent of the patients with cholesterol below 129 mg/l had died, but only half as many of the patients with cholesterol above 223 mg/l.


When proponents of the cholesterol hypothesis are confronted with findings showing a bad outcome associated with low cholesterol - and there are many such observations - they usually argue that severely ill patients are often malnourished, and malnourishment is therefore said to cause low cholesterol.


However, the mortality of the patients in this study was independent of their degree of nourishment; low cholesterol predicted early mortality whether the patients were malnourished or not.



So Why Does Mainstream Medicine Demonize LDL Cholesterol?

Could it be because it benefits the billion-dollar cholesterol drug industry?


Statin drugs are taken by one in four Americans over age of 45, and if patients stopped buying cholesterol drugs, Big Pharma would be in a serious financial crisis.


In fact, as soon as the study's cancer findings were published, a heart "expert" immediately warned that,

"statins used for LDL reduction shouldn't be stopped if there is an appropriate use to lower heart disease risk."

So mainstream medicine's advice is to hang onto these "miracle drugs" even though they have been linked to,

...and now cancer.

Even a world renowned heart surgeon with 25 years experience, having performed over 5,000 open-heart surgeries has admitted he was wrong about what really causes heart disease, and it's not high cholesterol.

Statins artificially lower cholesterol levels by inhibiting a critical enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. The consequences are inflammation and pathological breakdown of physiological systems.


In the long run, statins are going to be a bonanza, but for the trial lawyers, not the drug companies. But by then it will be too late for those taking them now.


We need to reform education on what really causes heart disease and why cholesterol, whether high or low, is not an evil process in the body, but a natural part of our biology.


When we stop listening to medical doctors, suddenly we start listening to what our bodies crave... to be the healthiest version of ourselves.